Poprzedni Temat

Kliniczne aspekty chorób układu limfatycznego: część 1 i 2 | Clinical Aspects of Lymphatic Diseases: part 1 and 2

Tooltip .tooltip { position: relative; cursor: pointer; text-decoration: none; border-bottom: 1px dashed rgba(0, 0, 0, 0.6); } .tooltip::before { content: attr(data-tooltip); position: absolute; top: -40px; /* Trochę niżej nad słowem */ left: 50%; /* Wyśrodkowanie */ transform: translateX(-50%); background-color: rgba(255, 255, 255, 0.9); color: #333; padding: 6px 12px; border-radius: 8px; white-space: nowrap; opacity: 0; visibility: hidden; transition: opacity 0.3s ease, visibility 0.3s ease; font-family: ‘Arial’, sans-serif; font-size: 14px; box-shadow: 0px 4px 8px rgba(0, 0, 0, 0.1); z-index: 10; } .tooltip:hover::before { opacity: 1; visibility: visible; } document.addEventListener(‘DOMContentLoaded’, function () { const wordsToTooltip = { “Castleman disease”: “Choroba Castleman”, “Unicentric Castleman Disease”: “Jednoogniskowa postać choroby Castleman”, “Multicentric Castleman Disease”: “Wieloogniskowa postać choroby Castleman”, “Human herpesvirus 8”: “Ludzki wirus opryszczki typu 8”, “Enlarged lymph node”: “Powiększony węzeł chłonny”, “Fever”: “Gorączka”, “Night sweats”: “Nocne poty”, “Weight loss”: “Utrata masy ciała”, “Generalized lymphadenopathy”: “Uogólniona limfadenopatia”, “Fatigue”: “Zmęczenie”, “Organomegaly”: “Powiększenie narządów”, “Skin rashes”: “Wysypki skórne”, “Neuropathy”: “Neuropatia”, “CT scans”: “Tomografia komputerowa (TK)”, “MRI scans”: “Rezonans magnetyczny (MRI)”, “Lymph node biopsy”: “Biopsja węzłów chłonnych”, “Histological examination”: “Badanie histopatologiczne”, “CRP”: “CRP (Białko C-reaktywne)”, “C-reactive protein”: “Białko C-reaktywne”, “ESR”: “OB (Odczyn Biernackiego)”, “Erythrocyte sedimentation rate”: “Odczyn Biernackiego (OB)”, “Anemia”: “Niedokrwistość”, “Liver function tests”: “Badania czynności wątroby”, “HHV-8-associated cases”: “Przypadki związane z HHV-8”, “Surgical removal”: “Chirurgiczne usunięcie”, “Radiation therapy”: “Radioterapia”, “Monoclonal antibodies”: “Przeciwciała monoklonalne”, “Siltuximab”: “Siltuksymab”, “Rituximab”: “Rytuksymab”, “Antiviral therapy”: “Terapia przeciwwirusowa”, “Corticosteroids”: “Kortykosteroidy”, “Chemotherapy”: “Chemioterapia”, “Recurrent infections”: “Nawracające infekcje”, “Organ failure”: “Niewydolność narządów”, “Secondary malignancies”: “Wtórne nowotwory złośliwe”, “Amyloidosis”: “Amyloidoza”, “Unicentric Castleman Disease prognosis”: “Rokowanie w jednoogniskowej postaci choroby Castleman”, “Multicentric Castleman Disease prognosis”: “Rokowanie w wieloogniskowej postaci choroby Castleman”, “Lymphatic filariasis”: “Filarioza limfatyczna”, “Elephantiasis”: “Słoniowacizna”, “Filarial worms”: “Nicienie filarie”, “Wuchereria bancrofti”: “Wuchereria bancrofti”, “Brugia malayi”: “Brugia malayi”, “Brugia timori”: “Brugia timori”, “Mosquito bites”: “Ukąszenia komarów”, “Lymphangitis”: “Zapalenie naczyń limfatycznych”, “Lymphadenitis”: “Zapalenie węzłów chłonnych”, “Filarial fever”: “Gorączka filariozowa”, “Hydrocele”: “Wodniak jądra”, “Microfilariae”: “Mikrofilarie”, “Diethylcarbamazine”: “Dietylokarbamazyna”, “DEC”: “DEC (Dietylokarbamazyna)”, “Ivermectin”: “Iwermektyna”, “Albendazole”: “Albendazol”, “Compression therapy”: “Terapia uciskowa”, “Chronic disability”: “Przewlekła niepełnosprawność”, “Hodgkin lymphoma”: “Chłoniak Hodgkina”, “Reed-Sternberg cells”: “Komórki Reeda-Sternberga”, “Epstein-Barr Virus”: “Wirus Epsteina-Barr”, “EBV”: “EBV (Wirus Epsteina-Barr)”, “Immunosuppression”: “Immunosupresja”, “B symptoms”: “Objawy B”, “Pruritus”: “Świąd”, “Ann Arbor staging system”: “Klasyfikacja Ann Arbor”, “Pel–Ebstein fever”: “Gorączka Pel-Ebsteina”, “Drenching night sweats”: “Obfite nocne poty”, “Extranodal involvement”: “Zajęcie pozawęzłowe”, “PET-CT scans”: “Badania PET-CT”, “ABVD regimen”: “Schemat ABVD”, “Adriamycin”: “Adriamycyna”, “Bleomycin”: “Bleomycyna”, “Vinblastine”: “Winblastyna”, “Dacarbazine”: “Dakarbazyna”, “Brentuximab vedotin”: “Brentuksymab wedotyna”, “Secondary cancers”: “Wtórne nowotwory złośliwe”, “Cardiopulmonary toxicity”: “Toksyczność kardiopłucna”, “Infertility”: “Niepłodność”, “Non-Hodgkin lymphoma”: “Chłoniak nieziarniczy”, “NHL”: “Chłoniak nieziarniczy (NHL)”, “B-cell lymphomas”: “Chłoniaki z komórek B”, “T-cell lymphomas”: “Chłoniaki z komórek T”, “Sjogren’s syndrome”: “Zespół Sjögrena”, “Lupus”: “Toczeń”, “Uncontrolled proliferation of lymphocytes”: “Niepohamowana proliferacja limfocytów”, “Lymphadenopathy”: “Limfadenopatia”, “Systemic symptoms”: “Objawy ogólnoustrojowe”, “Abdominal pain”: “Ból brzucha”, “Skin lesions”: “Zmiany skórne”, “Immunophenotyping”: “Immunofenotypowanie”, “CHOP regimen”: “Schemat CHOP”, “Cyclophosphamide”: “Cyklosporyna”, “Doxorubicin”: “Doksorubicyna”, “Vincristine”: “Winkrystyna”, “Prednisone”: “Prednizon”, “CAR-T cell therapy”: “Terapia CAR-T”, “Tumor lysis syndrome”: “Zespół rozpadu guza”, “Indolent lymphomas”: “Chłoniaki indolentne”, “Aggressive lymphomas”: “Chłoniaki agresywne” }; // Normalize keys in the dictionary const normalizedWordsToTooltip = {}; for (const [key, value] of Object.entries(wordsToTooltip)) { const cleanedKey = key.replace(/(.*?)/g, ”).trim(); // Remove anything in parentheses normalizedWordsToTooltip[cleanedKey.toLowerCase()] = value; } function processNode(node) { if (node.nodeType === Node.TEXT_NODE && node.nodeValue.trim()) { let content = node.nodeValue; // Regex to match only the main words (ignores parentheses) const regex = new RegExp( `\b(${Object.keys(normalizedWordsToTooltip).join(‘|’)})\b`, ‘gi’ ); if (regex.test(content)) { const wrapper = document.createElement(‘span’); wrapper.innerHTML = content.replace(regex, (match) => { const tooltip = normalizedWordsToTooltip[match.toLowerCase().trim()]; return `${match}`; }); node.replaceWith(wrapper); } } else if (node.nodeType === Node.ELEMENT_NODE) { Array.from(node.childNodes).forEach(processNode); } } document.querySelectorAll(‘body *:not(script):not(style)’).forEach((element) => { Array.from(element.childNodes).forEach(processNode); }); });

Castleman Disease

Castleman disease is a rare disorder characterized by the abnormal growth of lymph node tissue. It can be classified into two types: unicentric (affecting a single lymph node) and multicentric (involving multiple lymph nodes and systemic symptoms).

Etiology

  • Unicentric Castleman Disease: The cause is largely unknown and tends to affect a single lymph node or a group of nodes.
  • Multicentric Castleman Disease: Often associated with infections such as human herpesvirus 8 (HHV-8), and more commonly seen in people with weakened immune systems, such as those with HIV/AIDS.

Pathophysiology

  • Unicentric: Involves localized overgrowth of lymphoid tissue, usually without systemic involvement.
  • Multicentric: Characterized by widespread lymph node enlargement and systemic inflammation. The excess production of pro-inflammatory cytokines, particularly interleukin-6 (IL-6), contributes to the disease’s systemic effects.

Clinical Manifestations

  • Unicentric Castleman Disease:
    • Usually asymptomatic and discovered incidentally.
    • Enlarged lymph node: A single, non-tender mass that may compress nearby organs and cause symptoms such as difficulty breathing or swallowing.
  • Multicentric Castleman Disease:
    • Fever, night sweats, and weight loss.
    • Generalized lymphadenopathy: Enlargement of multiple lymph nodes.
    • Fatigue and weakness.
    • Organomegaly: Enlarged liver or spleen.
    • Skin rashes and neuropathy.

Diagnostic Approach

  • Imaging Studies: CT or MRI scans to identify lymph node enlargement and assess organ involvement.
  • Lymph Node Biopsy: Definitive diagnosis based on histological examination.
  • Blood Tests: Elevated inflammatory markers (CRP, ESR), anemia, and abnormal liver function tests.
  • Viral Testing: Screening for HHV-8 and HIV, particularly in multicentric cases.

Treatment

  1. Unicentric Castleman Disease:
    • Surgical Removal: Complete excision of the affected lymph node often cures the disease.
    • Radiation Therapy: An option if surgery is not feasible.
  2. Multicentric Castleman Disease:
    • Immunotherapy: Monoclonal antibodies targeting IL-6 (e.g., siltuximab) or CD20 (e.g., rituximab).
    • Antiviral Therapy: For HHV-8-associated cases.
    • Corticosteroids: To reduce inflammation and manage symptoms.
    • Chemotherapy: For severe or refractory cases.

Complications

  • Infections: Due to immunosuppression, patients are at higher risk.
  • Organ Failure: Severe cases can lead to liver or kidney dysfunction.
  • Secondary Malignancies: Increased risk of developing lymphomas.
  • Amyloidosis: Abnormal protein deposits that can affect organ function.

Prognosis for Castleman Disease

  • Unicentric Castleman Disease (UCD): Generally favorable, with a 5-year survival rate exceeding 90% after complete surgical removal. Recurrence is rare, and most patients achieve full recovery following treatment.
  • Multicentric Castleman Disease (MCD): Prognosis is more variable, with a 5-year survival rate ranging from 65-75%, depending on factors such as the underlying cause (e.g., HIV or HHV-8 infection) and response to treatment. Lifelong management may be necessary, as MCD can be life-threatening despite recent advances in therapy.

Lymphatic Filariasis

Lymphatic filariasis, also known as elephantiasis, is a parasitic infection caused by filarial worms (Wuchereria bancrofti, Brugia malayi, and Brugia timori) that are transmitted through mosquito bites. The disease primarily affects the lymphatic system, causing chronic swelling and disability.

Etiology

  • Causative Agents: Wuchereria bancrofti (most common), Brugia malayi, and Brugia timori.
  • Transmission: Spread by mosquitoes that carry the infective larvae. When the mosquito bites a human, the larvae enter the bloodstream and migrate to the lymphatic system.

Pathophysiology

The filarial worms lodge in the lymphatic vessels, where they mature and reproduce, causing inflammation and blockage. The chronic obstruction of lymphatic flow leads to lymphedema, fibrosis, and thickening of the skin and tissues. Repeated infections exacerbate lymphatic damage and lead to severe disfigurement and disability.

Clinical Manifestations

  1. Acute Phase:
    • Fever and chills.
    • Lymphangitis and lymphadenitis: Painful, swollen lymph nodes.
    • Filarial fever: An acute systemic febrile illness.
  2. Chronic Phase:
    • Lymphedema: Swelling of the limbs, genitals, or breasts.
    • Elephantiasis: Severe thickening of the skin and underlying tissues.
    • Hydrocele: Swelling of the scrotum, common in men.
    • Recurrent bacterial infections: Due to compromised lymphatic function.

Diagnostic Approach

  • Microscopic Examination: Detection of microfilariae in a blood smear, collected at night when the parasites are most active.
  • Serology: Blood tests to detect filarial antigens or antibodies.
  • Ultrasound: To visualize adult worms in the lymphatic system.
  • PCR: Molecular testing for more accurate detection.

Treatment

  1. Antiparasitic Medications:
    • Diethylcarbamazine (DEC): Kills microfilariae and some adult worms.
    • Ivermectin: Used in combination with DEC or albendazole in mass drug administration programs.
    • Albendazole: Often combined with other drugs to improve effectiveness.
  2. Management of Lymphedema:
    • Hygiene: Regular washing and skin care to prevent infections.
    • Exercise: To promote lymphatic drainage.
    • Compression Therapy: To reduce swelling.
  3. Surgical Intervention: In cases of severe hydrocele or elephantiasis.

Complications

  • Chronic Disability: Severe lymphedema and elephantiasis can lead to significant physical and social disability.
  • Recurrent Infections: Skin and soft tissue infections are common.
  • Psychological Impact: Stigmatization and mental health issues due to disfigurement.

Prognosis for Lymphatic Filariasis

  • Early Treatment: With prompt administration of antiparasitic medications, the infection can be controlled, and progression to chronic complications may be prevented. However, existing lymphatic damage is often irreversible, and long-term management may be required.
  • Chronic Stage: Once lymphedema or elephantiasis develops, the prognosis becomes more challenging. While these conditions are not life-threatening, they significantly impact quality of life and may require lifelong care to manage swelling and prevent secondary infections.

Hodgkin Lymphoma

Hodgkin lymphoma is a type of cancer that originates in the lymphatic system, characterized by the presence of Reed-Sternberg cells. It is one of the most treatable forms of cancer, particularly when detected early.

Etiology and Risk Factors

  • Epstein-Barr Virus (EBV): Infection with EBV increases the risk.
  • Family History: A family history of lymphoma is a significant risk factor.
  • Immunosuppression: HIV/AIDS or use of immunosuppressive drugs.
  • Age and Gender: Most common in young adults (ages 15-35) and older adults over 55, with a slightly higher prevalence in males.

Pathophysiology

Reed-Sternberg cells, which are large, abnormal B lymphocytes, are the hallmark of Hodgkin lymphoma. The cancerous cells accumulate in lymph nodes, causing them to enlarge and disrupt normal immune function. The disease can spread to nearby lymph nodes, organs, and bone marrow.

Clinical Manifestations

  • Painless Lymphadenopathy: Swollen lymph nodes, usually in the neck, underarm, or groin.
  • Systemic “B Symptoms”: Fever, night sweats, and unintentional weight loss. These symptoms are crucial in the staging and prognosis of Hodgkin lymphoma and are part of the Ann Arbor staging system, which is used to determine the extent of the disease.
  • Fatigue and Weakness: Due to anemia or the cancer’s systemic effects.
  • Pruritus: Severe itching, sometimes before the onset of lymph node swelling.
  • Alcohol-Induced Pain: Some patients experience pain in the lymph nodes after drinking alcohol.

Ann Arbor Staging System

The Ann Arbor staging system is used to classify both Hodgkin and Non-Hodgkin lymphoma based on the extent of the disease and the presence of systemic symptoms. This system helps guide treatment decisions and predict prognosis. The staging includes four principal stages:

StageDescription
Stage ICancer is limited to one lymph node region or a single extralymphatic site.
Stage IICancer involves two or more lymph node regions on the same side of the diaphragm.
Stage IIICancer is present on both sides of the diaphragm and may include involvement of the spleen or a nearby organ.
Stage IVDiffuse or widespread involvement of one or more extralymphatic organs, such as the liver or bone marrow.

Modifiers

The Ann Arbor system uses additional letters (A, B, E, S, X) to provide more details about the disease’s characteristics and symptoms, which can influence prognosis and treatment options. These modifiers add important context to the numerical stage of the disease:

  • A: Indicates the absence of systemic symptoms. Patients do not experience significant symptoms like fever, night sweats, or weight loss.
  • B: Indicates the presence of systemic symptoms, which are known as “B symptoms”. These symptoms have prognostic significance and include:
    • Fever: A temperature greater than 38 °C. The fever may follow any pattern but can sometimes manifest as a classic Pel–Ebstein fever, characterized by intermittent fever episodes lasting 1–2 weeks, followed by afebrile periods.
    • Drenching Night Sweats: Profuse sweating that occurs at night and soaks through sleepwear or bed sheets.
    • Unintentional Weight Loss: A loss of more than 10% of normal body weight over 6 months or less, without dieting or other intentional efforts.
  • E: Denotes extranodal involvement, meaning the cancer has spread outside of the lymph nodes to an adjacent organ or tissue.
  • S: Indicates involvement of the spleen.
  • X: Refers to bulky disease, where the largest tumor deposit is greater than 10 cm in size or the mediastinal mass is wider than one-third of the chest’s width on a chest X-ray.

Diagnostic Approach

  • Lymph Node Biopsy: The definitive diagnosis, showing Reed-Sternberg cells under the microscope.
  • Imaging Studies: PET-CT scans to stage the disease and assess the extent of lymph node involvement.
  • Blood Tests: To evaluate organ function and detect signs of systemic involvement.

Treatment

  1. Chemotherapy: ABVD regimen (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) is commonly used.
  2. Radiation Therapy: Often used in combination with chemotherapy for localized disease.
  3. Immunotherapy: Monoclonal antibodies like brentuximab vedotin for relapsed or refractory disease.
  4. Stem Cell Transplant: Considered for patients who do not respond to initial treatment.

Complications

  • Secondary Cancers: Increased risk of other malignancies, particularly with long-term follow-up.
  • Cardiopulmonary Toxicity: From chemotherapy and radiation therapy.
  • Infections: Due to immune suppression from both the disease and its treatment.
  • Infertility: Potential side effect of chemotherapy.

Prognosis for Hodgkin Lymphoma

  • Favorable in Early Stages: The 5-year survival rate for early-stage Hodgkin Lymphoma is around 90-95% with appropriate treatment, such as chemotherapy and radiation. Early diagnosis and intervention lead to excellent outcomes for most patients.
  • Advanced Stages: The 5-year survival rate for advanced-stage disease ranges from 70-85%, depending on factors such as age, overall health, and response to therapy. Advances in treatment have significantly improved outcomes even for those with more extensive disease.

Non-Hodgkin Lymphoma (NHL)

Non-Hodgkin lymphoma (NHL) encompasses a diverse group of blood cancers that originate in the lymphatic system, affecting either B cells or T cells. It is more common than Hodgkin lymphoma and has a wide range of presentations and outcomes.

Etiology

  • Genetic Mutations: Alterations in genes that control cell growth.
  • Infections: Viruses like HIV, Epstein-Barr virus, and Helicobacter pylori infection.
  • Autoimmune Disorders: Conditions like Sjögren’s syndrome and lupus increase the risk.
  • Immunosuppression: Organ transplant recipients and patients with HIV/AIDS.
  • Chemical Exposure: Pesticides and herbicides have been linked to NHL.

Pathophysiology

NHL results from the uncontrolled proliferation of lymphocytes, which can form tumors in lymph nodes or other organs. The disease is classified based on the type of lymphocyte involved (B-cell or T-cell) and its growth pattern (indolent or aggressive). The abnormal lymphocytes accumulate in lymphoid tissues, disrupting normal immune function.

Clinical Manifestations

  • Lymphadenopathy: Painless swelling of lymph nodes in the neck, armpit, or groin.
  • Systemic Symptoms: Fever, night sweats, and weight loss (B symptoms).
  • Abdominal Pain or Swelling: Due to enlarged lymph nodes or involvement of abdominal organs.
  • Fatigue: Commonly reported by patients.
  • Chest Pain or Cough: If lymph nodes in the chest are enlarged.
  • Skin Lesions: In some types of T-cell lymphomas.

Diagnostic Approach

  • Lymph Node Biopsy: Essential for diagnosis and classification.
  • Immunophenotyping: To determine the type of lymphoma (B-cell or T-cell).
  • Imaging Studies: PET-CT scans to stage the disease.
  • Bone Marrow Biopsy: To assess bone marrow involvement.

Treatment

  1. Chemotherapy: CHOP regimen (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) is commonly used.
  2. Targeted Therapy: Rituximab for B-cell lymphomas.
  3. Radiation Therapy: Used for localized disease or to reduce tumor burden.
  4. Stem Cell Transplant: For aggressive or relapsed cases.
  5. Immunotherapy: CAR-T cell therapy for refractory disease.

Complications

  • Infections: Due to weakened immune function.
  • Tumor Lysis Syndrome: A metabolic emergency that occurs when cancer cells break down rapidly.
  • Secondary Cancers: Long-term risk following treatment.
  • Organ Dysfunction: Due to tumor infiltration or treatment-related side effects.

Prognosis for Non-Hodgkin Lymphoma (NHL)

  • Varies by Subtype and Stage: The 5-year survival rate for NHL ranges from 60-90%, depending on the lymphoma subtype, stage at diagnosis, and factors like age and overall health. Indolent (slow-growing) types often have a favorable long-term outlook but may require ongoing monitoring, while aggressive forms need intensive treatment.

Strona: 1 2